Gyre Therapeutics, Inc. Accrued Income Taxes, Current
Gyre Therapeutics, Inc. (GYRE) had Accrued Income Taxes, Current of $2.15 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2026-08-07
- 2026-06-30: Accrued Income Taxes, Current $2.15M.
- 2026-03-31: Accrued Income Taxes, Current $3.13M.
- 2025-12-31: Accrued Income Taxes, Current $2.94M.
- 2025-09-30: Accrued Income Taxes, Current $2.65M.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2026-06-30 | $2.15M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $3.13M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $2.94M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $2.65M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $1.08M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $569.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $2.83M 10-K · filed 2026-03-13 |
| 2024-09-30 | $2.84M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.26M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $6.47M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $5.05M 10-K · filed 2025-03-17 |
| 2022-12-31 | $2.10M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |